<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01222559</url>
  </required_header>
  <id_info>
    <org_study_id>cod16HS13</org_study_id>
    <secondary_id>2009-016466-82</secondary_id>
    <nct_id>NCT01222559</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of co.Don Chondrosphere to Treat Cartilage Defects</brief_title>
  <official_title>Prospective, Randomised, Open Label, Multicentre Phase-III Clinical Trial to Compare the Efficacy and Safety of the Treatment With the Autologous Chondrocyte Transplantation Product co.Don Chondrosphere (ACT3D-CS) With Microfracture in Subjects With Cartilage Defects of the Knee With a Defect Size Between 1 an 4 cm2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>co.don AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>co.don AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, phase III, multicenter, open label, randomised clinical trial of&#xD;
      co.don chondrosphere®, a three-dimensional autologous chondrocyte transplantation product&#xD;
      (ACT3D-CS)compared to the procedure of microfracture (MF)in the treatment of cartilage&#xD;
      defects of knee joints.&#xD;
&#xD;
      After screening visit patients were booked for arthroscopy and at that time they were&#xD;
      randomised to either ACT3D-CS with co.don chondrosphere® (Group A) or to MF(Group B), a&#xD;
      marrow-stimulating method based on the penetration of the subchondral bone plate at the&#xD;
      bottom of the cartilage defect. At the time of arthroscopy Patients of group B had their&#xD;
      procedure of MF (treatment surgery) and patients of group A had their cells harvested from&#xD;
      healthy cartilage. The cells are cultivated for 8-10 weeks in vitro to develope 3-dimensional&#xD;
      spheroids , that are transplanted in an open knee procedure (treatment surgery)into the&#xD;
      defect. Patients subsequently followed the same rehabilitation program and had post-surgery&#xD;
      visits. After the 12-month-visit a interim analyses will be performed and the 24-month-visit&#xD;
      is defined as final assessment. Then patients have follow-up assessments up to 60 months&#xD;
      post-treatment-surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      see above&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">February 2020</completion_date>
  <primary_completion_date type="Actual">September 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of overall KOOS</measure>
    <time_frame>24 months after the end of the respective treatment</time_frame>
    <description>Change of overall KOOS (Knee Injury and Osteoarthritis Outcome Score)from baseline (Day 0)to final assessment compared between ACT3D-CS (co.don chondrosphere) and MF (microfracture)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of overall KOOS</measure>
    <time_frame>12, 36, 48, 60 months after the end of the respective treatment</time_frame>
    <description>Change of overall KOOS(Knee Injury and Osteoarthritis Outcome Score) from baseline (Day 0) to 12 months, 36, 48, 60 months after the end of the respective treatment,compared between ACT3D-CS and MF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the 5 subscores of the KOOS</measure>
    <time_frame>12, 24, 36, 48, 60 months after the end of the respective treatment</time_frame>
    <description>Change of the 5 subscores of the KOOS (Pain, other Symptoms, Function in daily living (ADL), Function in sport and recreation (Sport/Rec), knee related Quality of life (QoL)) for both treatment groups compared between ACT3D-CS and MF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MOCART (MRI Score)</measure>
    <time_frame>12, 24, 36, 48 and 60 months after transplantation or microfracture</time_frame>
    <description>MOCART (MRI Score) 12, 24, 36, 48 and 60 months after transplantation or microfracture compared between ACT3D-CS and MF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arthroscopy and biopsy</measure>
    <time_frame>24 months</time_frame>
    <description>Arthroscopy and biopsy at 24 months after transplantation/ microfracture, assessment of cartilage repair after ACT3D and microfracture to be compared between ACT3D-CS and MF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICRS Visual Histological Assessment Score</measure>
    <time_frame>24 months after respective treatment</time_frame>
    <description>ICRS Visual Histological Assessment Score at final assessment (24 months) compared between ACT3D-CS and MF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bern Score and additional histological assessment scores</measure>
    <time_frame>24 months after the respective treatment</time_frame>
    <description>Bern Score and additional histological assessment scores at final assessment (24 months) compared between ACT3D-CS and MF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of ICRS/IKDC</measure>
    <time_frame>12, 24, 36, 48 and 60 months after the end of the respective treatment</time_frame>
    <description>Change of ICRS/IKDC from baseline (Day 0) to 12, 24, 36, 48 and 60 months after the end of the respective treatment, compared between ACT3D-CS and MF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of modified Lysholm Score</measure>
    <time_frame>12, 24, 36, 48 and 60 months after the end of the respective treatment</time_frame>
    <description>Change of modified Lysholm Score from baseline (Day 0) to 12, 24, 36, 48 and 60 months after the end of the respective treatment compared between ACT3D-CS and MF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days of absence from work (employment) and/or days of inability to follow usual activities</measure>
    <time_frame>annual</time_frame>
    <description>Days of absence from work (employment) and/or days of inability to follow usual activities during the last year or since the last visit, respectively, and time point when patient was back to work and/or to follow usual activities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Parameters</measure>
    <time_frame>3,12,24 months after respective treatment</time_frame>
    <description>Frequence and type of adverse Events Vital signs Physical examination Concomitant pain medication Laboratory parameters</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Articular Cartilage Lesion of the Femoral Condyle</condition>
  <arm_group>
    <arm_group_label>co.don chondrosphere®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>co.don chondrosphere® are spheroids in suspension, developed from autologous chondrocytes. The dose depends on the size of the defect, recommended dose is 10-70 spheroids/cm2 defect.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Micofracture</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A procedure in which the subchondral bone is perforated to allow a bloodcloth to form scar tissue.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>co.don chondrosphere®</intervention_name>
    <description>co.don chondrosphere® are spheroids in suspension, developed from autologous chondrocytes. The dose depends on the size of the defect, recommended dose is 10-70 spheroids/cm2 defect.</description>
    <arm_group_label>Micofracture</arm_group_label>
    <arm_group_label>co.don chondrosphere®</arm_group_label>
    <other_name>ACT3D-CS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Microfracture</intervention_name>
    <description>A procedure in which the subchondral bone is perforated to allow a bloodcloth to form new tissue.</description>
    <arm_group_label>Micofracture</arm_group_label>
    <other_name>Subchondral drilling</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients, age: between 18 and 50 years&#xD;
&#xD;
          2. Defect: isolated ICRS grade III or IV single defect chondral lesions on femoral&#xD;
             condyles&#xD;
&#xD;
          3. Defect size: 1 to &lt; 4 cm2 after debridement to healthy cartilage up to 6 mm in&#xD;
             depth.Assessment with MRI at screening and per estimation during arthroscopy prior to&#xD;
             randomization&#xD;
&#xD;
          4. Nearly intact chondral structure surrounding the defect as well as an intact&#xD;
             corresponding joint area&#xD;
&#xD;
          5. Informed consent signed and dated by patient&#xD;
&#xD;
          6. Patient understands the strict rehabilitation protocol and follow-up programme and is&#xD;
             willing to follow it&#xD;
&#xD;
          7. In case of pain, patient agrees to use only paracetamol mono- (max 4 g/day) or&#xD;
             combination preparation and oral and/or topic NSAIDs during the trial and to&#xD;
             discontinue the use of oral and/or topic NSAIDs and/or paracetamol combination&#xD;
             preparation 1 week before each visit whereas the use of paracetamol monopreparation&#xD;
             (max 4 g/day) is allowed. However, in the morning of the visit day, no pain medication&#xD;
             is allowed. Other pain medications are allowed during surgical procedure and may be&#xD;
             taken for a period not exceeding 4 weeks after surgery.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Defects on both knees at the same time&#xD;
&#xD;
          2. Radiological signs of osteoarthritis&#xD;
&#xD;
          3. Osteochondritis dissecans (OCD)&#xD;
&#xD;
          4. Any signs of knee instability&#xD;
&#xD;
          5. Valgus or varus malalignment (more than 5° over the mechanical axis)&#xD;
&#xD;
          6. Clinically relevant second cartilage lesion on the same knee&#xD;
&#xD;
          7. More than 50 % resection of a meniscus in the affected knee or incomplete meniscal rim&#xD;
&#xD;
          8. Rheumatoid arthritis, parainfectious or infectious arthritis, and condition after&#xD;
             these diseases&#xD;
&#xD;
          9. Pregnancy and planned pregnancy (no MRI possible)&#xD;
&#xD;
         10. Obesity (Body Mass Index &gt;30)&#xD;
&#xD;
         11. Uncontrolled diabetes mellitus&#xD;
&#xD;
         12. Serious illness&#xD;
&#xD;
         13. Poor general health as judged by physician&#xD;
&#xD;
         14. Participation in concurrent clinical trials or previous trials within 3 months of&#xD;
             screening&#xD;
&#xD;
         15. Previous treatment with ACT in the affected knee&#xD;
&#xD;
         16. Microfracture performed less than 1 year before screening in the affected knee&#xD;
&#xD;
         17. Alcohol or drug (medication) abuse&#xD;
&#xD;
         18. Meniscal transplant in the affected knee&#xD;
&#xD;
         19. Meniscal suture (in the affected knee) three months prior to baseline&#xD;
&#xD;
         20. Mosaicplasty (Osteoarticular Transplant System, OATS) in the affected knee&#xD;
&#xD;
         21. Having received hyaluronic acid intra-articular injections in the affected knee within&#xD;
             the last 3 months before baseline&#xD;
&#xD;
         22. Taking specific osteoarthritis drugs such as chondroïtin sulfate, diacerein,&#xD;
             nglucosamine,piascledine, capsaicin within 2 weeks before baseline&#xD;
&#xD;
         23. Corticosteroid treatment by systemic or intraarticular route within the last month of&#xD;
             baseline or intramuscular or oral corticosteroïds within the last 2 weeks before&#xD;
             baseline&#xD;
&#xD;
         24. Chronic use of anticoagulants&#xD;
&#xD;
         25. Any concomitant painful or disabling disease of the spine, hips or lower limbs that&#xD;
             would interfere with evaluation of the afflicted knee&#xD;
&#xD;
         26. Any clinically significant or symptomatic vascular or neurological disorder of the&#xD;
             lower extremities&#xD;
&#xD;
         27. Any evidence of the following diseases in the affected knee: septic arthritis,&#xD;
             inflammatory joint disease, recurrent episodes of pseudogout, Paget's disease of bone,&#xD;
             ochronosis, acromegaly, haemochromatosis, Wilson's disease, primary&#xD;
             osteochondromatosis, heritable disorders, collagen gene mutation&#xD;
&#xD;
         28. Current diagnosis of osteomyelitis, human immunodeficiency virus (HIV-1,-2) and/or&#xD;
             hepatitis C virus (HCV) infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Fickert, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsmedizin Mannheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinikum der Albert-Ludwig-Universität Freiburg, Department Othopädie und Traumatologie</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Würrtemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waldkrankenhaus &quot;Rudolf Elle&quot; GmbH Klinik für Orthopädie und Unfallchirurgie</name>
      <address>
        <city>Eisenberg</city>
        <state>Tühringen</state>
        <zip>07607</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gelenk-und Wirbelsäulenzentrum Steglitz</name>
      <address>
        <city>Berlin</city>
        <zip>12163</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DRK-Kliniken Westend</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vinzenz-Hospital</name>
      <address>
        <city>Dinslaken</city>
        <zip>46535</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orthopädische Klinik der Medizinischen Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lubinus Clinicum Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DRK Krankenhaus Luckenwalde</name>
      <address>
        <city>Luckenwalde</city>
        <zip>14943</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orthopädisch-Unfallchirurgisches Zentrum</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny w Białymstoku</name>
      <address>
        <city>Białystok</city>
        <zip>15-276</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewódzki Szpital Chirurgii Urazowej</name>
      <address>
        <city>Piekary Śląskie</city>
        <zip>62</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medycyny Sportowej</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 15, 2010</study_first_submitted>
  <study_first_submitted_qc>October 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2010</study_first_posted>
  <last_update_submitted>January 26, 2021</last_update_submitted>
  <last_update_submitted_qc>January 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cartilage defects</keyword>
  <keyword>Knee joint</keyword>
  <keyword>Femoral Condyle</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

